

VIRTUAL FORMAT
CEST Time

PROGRAMME OF LIVE SESSIONS: CEST timing

The programme below will take place live. This time schedule corresponds to **CEST timing**. [Click here: https://www.calculator.net/time-zone-calculator.html](https://www.calculator.net/time-zone-calculator.html) to adapt the CEST time schedule to your own time zone.

If you want to ask questions during the Panel Discussions, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting



**ESH Translational Research E-Conference
LYMPHOID MALIGNANCIES**

October 14-17, 2021

Chairpersons: Michael Hallek (Cologne), Georg Lenz (Münster), Laurie Sehn (Vancouver), Louis Staudt (Bethesda)

Advisory Board: Barbara Eichhorst (Cologne), Ricardo Dalla-Favera (New York), Frank Morschhauser (Lille), Laura Pasqualucci (New York), Stephan Stilgenbauer (Ulm), Andrei Thomas-Tikhonenko (Philadelphia)

Thursday, October 14, 2021

15:30–15:40 Welcome

SESSION I – B-cell development and lymphomagenesis

Chair (s): TBA

15:40-15:45 Introduction

15:45-16:05 BCR signaling in mature and malignant B-cells

Klaus Rajewsky (Cologne)

16:05-16:25 Mechanisms of the GCR and their involvement in lymphomagenesis

Laura Pasqualucci (NewYork)

16:25-16:45 Pathogenesis of Hodgkin lymphoma

Ralf Küppers (Duisburg)

16:45-17:05 Dissecting GCB DLBCL and its therapeutic implications

David Scott (Vancouver)

17:05-17:12 **Selected brief oral communication**

17:12-17:45 *Panel discussion*

17:45-17:55 *Coffee Break*

SESSION II – Genetics of malignant lymphomas and clonal evolution

Chair (s): TBA

17:55-18:00	Introduction	
18:00-18:20	The genetic landscape of mantle cell lymphoma	Elias Campo (Barcelona)
18:20-18:40	Novel molecular subtypes of aggressive lymphomas	Margaret Shipp (Boston)
18:40-19:00	Rational development of combination therapies for lymphoma	Louis Staudt (Bethesda)
19:00-19:20	Targeting genetic alterations in lymphoma	Andrew Davies (Southampton)
19:20-19:27	Selected brief oral communication	Speaker
19:27-20:00	<i>Panel discussion</i>	

Friday, October 15, 2021

SESSION III – Epigenetics in malignant lymphomas

Chair (s): TBA

14:00-14:05	Introduction	
14:05-14:25	Role of epigenetic aberrations in DLBCL	Ari Melnick (New York)
14:25-14:45	Epigenetic alterations in mantle cell lymphoma	José Ignacio Martín-Subero (Barcelona)
14:45-15:05	Epigenetics in T-cell lymphoma	Teresa Palomero Vazquez (New York)
15:05-15:25	Therapeutic potential of targeting epigenetic regulators	Franck Morschhauser (Lille)
15:25-15:32	Selected brief oral communication	Speaker
15:32-16:00	<i>Panel discussion</i>	

16:00-16:10 *Coffee Break*

SESSION IV – Deregulated proteome and metabolome

Chair (s): TBA

16:10-16:15	Introduction	
16:15-16:35	Pathogenetic proteomic alterations in lymphoma	Thomas Oellerich (Frankfurt)
16:35-16:55	Targeting the metabolome in B-cell lymphoma	Andrew Intlekofer (New York)
16:55-17:15	Targeting the Proteome in T-cell lymphoma	Kojo Elenitoba Johnson (Philadelphia)
17:15-17:22	Selected brief oral communication	Speaker

17:22-17:50 *Panel discussion*

SESSION V – Single cell analyses, circulating tumor DNA, MRD

Chair (s): TBA

17:50-17:55 Introduction

17:55-18:15 Single cell analyses in lymphoma

Bertrand Nadel (Marseille)

18:15-18:35 Single cell analyses in CLL

Dan Landau (New York)

18:35-18:55 Circulating tumor DNA in aggressive lymphomas

David Kurtz (Stanford)

18:55-19:15 Role of ctDNA, MRD in the clinic

Andy Rawstron (Leeds)

19:15-19:22 **Selected brief oral communication**

Speaker

19:22-19:50 *Panel discussion*

Saturday, October 16, 2021

13:30-14:30 Mentored Poster Walk

14:30-15:30 Possible slot for a satellite symposium

SESSION VI – Oncogenic signaling pathways

Chair (s): TBA

15:35-15:40 Introduction

15:40-16:00 Role of oncogenic BCR signaling in aggressive lymphomas

James D. Phelan (Bethesda)

16:00-16:20 Addiction to PI3K isoforms in DLBCL

Georg Lenz (Münster)

16:20-16:40 Oncogenic signaling in CLL

Adrian Wiestner (Bethesda)

16:40-17:00 Oncogenic signaling in T-cell lymphoma

Stephan Mathas (Berlin)

17:00-17:07 **Selected Brief Oral Communication**

Speaker

17:07-17:30 *Panel discussion*

17:40-18:40 Possible slot for a satellite symposium

18:45-19:45 Simultaneous Meet the Expert sessions (non-clinical)

19:45-20:30 Break

SESSION VII – Utilizing oncogenic signaling therapeutically

Chair (s): TBA

20:30-20:35 Introduction

20:35-20:55 Role of BCR inhibitors in the treatment of lymphoma

Wyndham Wilson (Bethesda)

20:55-21:15	Combining pathway inhibitors in the treatment of CLL	Michael Hallek (Cologne)
21:15-21:35	Targeting anti-apoptotic pathways beyond CLL	John Seymour (Melbourne)
21:35-21:55	Tailoring therapy in frontline DLBCL	Laurie Sehn (Vancouver)
21:55-22:02	Selected Brief Oral Communication	Speaker
22:02-22:35	<i>Panel discussion</i>	

Sunday, October 17, 2021

14:00-15:00 Possible slot for a satellite symposium

SESSION VIII –Immunologic approaches in the treatment of lymphomas

Chair (s): TBA

15:00-15:05	Introduction	
15:05-15:25	Utilizing checkpoint inhibitors	Pier Luigi Zinzani (Bologna)
15:25-15:45	Perspective of bispecific antibodies	Stephen Schuster (Philadelphia)
15:45-16:05	Update CAR T-cells	Caron Jacobson (Boston)
16:05-16:25	Targeting CD47 as a new treatment option for lymphoma	Ranjana Advani (Stanford)
16:25-16:45	CAR T-cell therapies in mantle cell lymphoma	Frederick Locke (Tampa)
16:45-17:05	Utilizing novel CAR T-cell constructs	Peter Borchmann (Cologne)
17:05-17:12	Selected Brief Oral Communication	Speaker
17:12-17:45	<i>Panel discussion</i>	
17:45-18:00	<i>Closing Remarks</i>	